BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
NYSE:BHC • CA0717341071
6.11 USD
+0.09 (+1.5%)
At close: Feb 25, 2026
6.11 USD
0 (0%)
After Hours: 2/25/2026, 8:04:00 PM
BHC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While BHC is still in line with the averages on profitability rating, there are concerns on its financial health. BHC has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC reported 4 times negative net income.
- BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of BHC (0.60%) is better than 79.17% of its industry peers.
- With an excellent Return On Invested Capital value of 7.78%, BHC belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 12.96%.
- The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC's Profit Margin of 1.53% is fine compared to the rest of the industry. BHC outperforms 79.17% of its industry peers.
- BHC's Operating Margin of 21.28% is amongst the best of the industry. BHC outperforms 89.06% of its industry peers.
- BHC's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 70.65%, BHC is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
- BHC has more shares outstanding than it did 1 year ago.
- BHC has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
- BHC has an Altman-Z score of 0.29. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of BHC (0.29) is comparable to the rest of the industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 21.00, BHC is doing good in the industry, outperforming 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.18
WACC6.6%
2.3 Liquidity
- BHC has a Current Ratio of 1.47. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.47, BHC is doing worse than 71.35% of the companies in the same industry.
- BHC has a Quick Ratio of 1.08. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- BHC's Quick ratio of 1.08 is on the low side compared to the rest of the industry. BHC is outperformed by 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- The Earnings Per Share has been decreasing by -1.13% on average over the past years.
- Looking at the last year, BHC shows a small growth in Revenue. The Revenue has grown by 6.66% in the last year.
- BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.02% on average over the next years.
- BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.38% yearly.
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 1.62 indicates a rather cheap valuation of BHC.
- Based on the Price/Earnings ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BHC to the average of the S&P500 Index (27.05), we can say BHC is valued rather cheaply.
- With a Price/Forward Earnings ratio of 1.42, the valuation of BHC can be described as very cheap.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 98.96% of the companies in the same industry.
- BHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.62 | ||
| Fwd PE | 1.42 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 95.31% of the companies listed in the same industry.
- BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.28 | ||
| EV/EBITDA | 6.43 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -7.27% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
5. Dividend
5.1 Amount
- BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.11
+0.09 (+1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners45.78%
Inst Owner Change-1.83%
Ins Owners10.79%
Ins Owner Change11.68%
Market Cap2.27B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (21.6%)
Short Float %1.66%
Short Ratio2.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)1.27%
PT rev (3m)2.53%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)-1.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.54%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)-0.48%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.62 | ||
| Fwd PE | 1.42 | ||
| P/S | 0.22 | ||
| P/FCF | 2.28 | ||
| P/OCF | 1.62 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.43 |
EPS(TTM)3.77
EY61.7%
EPS(NY)4.29
Fwd EY70.2%
FCF(TTM)2.68
FCFY43.82%
OCF(TTM)3.78
OCFY61.79%
SpS27.68
BVpS-1.49
TBVpS-44.41
PEG (NY)0.12
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.6%
ROIC/WACC1.18
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.07%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.